EMA plans to revise current guidance on quality issues for biosimilars
This article was originally published in SRA
Executive Summary
The European Medicines Agency is planning to revise its guideline dealing with quality requirements for similar biological medicinal products containing biotechnology-derived proteins as active substance1.